US health department to remove broad black box warning from three estrogen patch products
The action expands earlier label changes as the FDA says 29 companies have submitted proposed revisions to menopausal hormone therapy products.
- On Friday, the US health department approved removing the strictest "black box" warnings from labels of three estradiol transdermal patches, hormone therapies used to treat menopause symptoms in the United States.
- Women in the United States have struggled to find hormone replacement treatments for mood swings and hot flashes amid surging demand, prompting the FDA to work with manufacturers to boost estrogen patch supplies.
- Estrogen patch market output has doubled over the past year, and the FDA has expedited review and approval of 10 supplements this year, with two approved within the past week.
- Labeling changes for six menopausal hormone therapy products were expanded to remove warnings related to CVD, breast cancer, and probable dementia, clarifying risk-benefit associations for patients and doctors.
- The FDA is working expeditiously to address label modifications for remaining menopausal hormone therapy products, though scarcities have previously impacted certain vaginal and injectable estrogen options despite no official shortage designation.
11 Articles
11 Articles
HHS updates safety labels for three more menopausal hormone therapy products
HHS approved updated labels for three additional menopausal hormone therapy products today.The agency took action on the products — estradiol transdermal patches which come from two applicants — through the FDA, according to a press release from HHS.
The Independent
Menopause patch black box warnings removed as American women face treatment shortages
The decision follows earlier revisions in February, when the FDA authorized the removal of warnings regarding breast cancer, cardiovascular disease, and probable dementia
US health department to remove broad black box warning from three estrogen patch products
The US health department on Friday approved the removal of the strictest "black box" warnings from the labels of three estradiol transdermal patches, the hormone therapies used to treat menopause symptoms.
FDA again bypasses advisers to remove black-box warnings from menopause treatments
Three more patches for treating menopause will no longer carry black-box warnings about cardiovascular disease, breast cancer and dementia, officials at the US Food and Drug Administration (FDA) said on Friday. The FDA did not convene an advisory committee and offered few details on the scientific…
Coverage Details
Bias Distribution
- 38% of the sources lean Left, 37% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
